The role of p16 as putative biomarker for cervical neoplasia: A controversial issue?

Gonçalves, Jessica E.S.; Andrade, Cecilia Vianna de; Russomano, Fabio B; Nuovo, Gerard J; Amaro-Filho, Sergio M; Carvalho, Maria OO; Nicol, Alcina Frederica

doi:10.5935/MedicalExpress.2017.06.01

Brasil

Español English

ORIGINAL RESEARCH • MedicalExpress (São Paulo, online) 4 (6) • Nov-Dec 2017 • https://doi.org/10.5935/MedicalExpress.2017.06.01 copy

The role of p16 as putative biomarker for cervical neoplasia: A controversial issue?

O Papel da Proteina p16 como marcador putativo para neoplasia cervical: um tema controverso?

Authorship SCIMAGO INSTITUTIONS RANKINGS

INTRODUCTION:

Protein p16 has been extensively studied as a potential biomarker for precursor lesions to distinguish cervical Intraepithelial neoplasia (CIN) from their mimics. However, the use of p16 as prognostic biomarker for diagnosis of cervical cancer and precancer is controversial. This study focuses on the assessment of peer-reviewed scientific data related to the use of p16 to predict disease severity and its controversies.

METHODS:

We reviewed publications in MEDLINE/PubMed assessing the clinical, diagnostic and prognostic significance of p16 in CIN and cervical cancer; we included publications from 2009 to June 2017.

RESULTS:

The use of p16 as a prognostic marker is still unreliable, although it could be a useful tool for diagnosis of Cervical Intraepithelial Neoplasia lesions with undetermined morphology. Moreover, p16 appears to be a specific marker of high-risk oncogenic HPV infection.

CONCLUSION:

This review shows the potential utility and drawbacks of p16 for clinical practice and the diagnosis of cervical cancer. Further studies are required to substantiate the role of p16 in conjunction with other more sensitive and specific biomarkers for diagnosing CIN and predicting its progression.

KEYWORDS:
p16 protein; HPV infection; cervical cancer; biomarker; cervical intraepithelial lesion

REFERENCES	NUMBER OF SAMPLES	HISTOLOGY	CONCLUSIONS
LIU et al, 2015 ²⁷27 Liu HQ, Wang YH, Wang LL, Hao M. P16INK4A and survivin: Diagnostic and prognostic markers in cervical intraepithelial neoplasia and cervical squamous cell carcinoma. Exp Mol Pathol. 2015;99(1):44-9. DOI:10.1016/j.yexmp.2015.04.004 https://doi.org/10.1016/j.yexmp.2015.04....	380	Normal/CIN 1,2,3 and SCC	p16 positively correlated with the grade of cervical diseases.
MILLS et al,2015 ²²22 Mills AM, Paquette C, Castle PE, Stoler MH. Risk stratification by p16 immunostaining of CIN1 biopsies: a retrospective study of patients from the quadrivalent HPV vaccine trials. Am J Surg Pathol. 2015;39(5):611-7. DOI:10.1097/PAS.0000000000000374 https://doi.org/10.1097/PAS.000000000000...	524	CIN 1,2,3	p16 should only be used selectively for problematic scenarios, such as CIN2.
KRISHNAPPA et al, 2014 ¹¹11 Krishnappa P, Mohamad IB, Lin YJ, Barua A. Expression of P16 in high- risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia. Diagn Pathol. 2014;9:202. DOI:10.1186/s13000-014-0202-z https://doi.org/10.1186/s13000-014-0202-...	75	Cervicitis / in situ carcinoma	p16 may be useful to diagnose between the low- and high-grade cervix lesions.
ZHANG et al, 2015 ²³23 Zhang G, Yang B, Abdul-Karim, FW. p16 Immunohistochemistry is Useful in Confirming High-grade Squamous Intraepithelial Lesions (HSIL) in Women with Negative HPV Testing. Int J Gynecol Pathol. 2015;34(2):180-6. DOI:10.1097/PGP.0000000000000112 https://doi.org/10.1097/PGP.000000000000...	46	Cervices Negative for high risk HPV	p16 may be a useful biomarker for CIN2-3
GUSTINUCCI et al, 2012 ²⁴24 Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S, et al. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program. Acta Cytol. 2012;56(5):506-14. DOI:10.1159/000338979 https://doi.org/10.1159/000338979...	578	cythology with	p16 can be considered as a good biomarker
GENOVÉS et al, 2014 ¹³13 Genovés J, Alameda F, Mancebo G, Solé JM, Bellozillo B, Lloveras B, et al. Human papillomavirus detection and p16INK4a expression in cervical lesions: a comparative study. Hum Pathol. 2014;45(4):826-33. DOI:10.1016/j.humpath.2013.10.035 https://doi.org/10.1016/j.humpath.2013.1...	86	CIN1,2,3	Negative p16 in cervical dysplasia does not always imply regression of the lesion
RAZMPOOSH et al, 2014 ²¹21 Razmpoosh M, Sansregret A, Oligny LL, Patey N, Dormoy-Raclet V, Ducruet T, et al. Assessment of Correlation Between p16INK4a Staining, Specific Subtype of Human Papillomavirus, and Progression of LSIL/CIN1 Lesions: First Comparative Study. Am J Clin Pathol. 2014;142(1):104-10. DOI:10.1309/AJCPBX74QXCPXIKK https://doi.org/10.1309/AJCPBX74QXCPXIKK...	64	CIN 1	P16 may be useful as prognostic biomarker for CIN1
PACCHIARIOTTI et al, 2013 ¹⁴14 Pacchiariotti A, Ferrari F, Bellardini P, Chini F, Collina G, Palma DP, et al. Prognostic value of p16-INK4A protein in women with negative or CIN1 histology result: A follow-up study. Int. J. Cancer, 2014;134(4): 897-904. DOI:10.1002/ijc.28407 https://doi.org/10.1002/ijc.28407...	369	CIN 1	P16 may be useful as prognostic biomarker for CIN1 (with restrict utilization)
NICOL et al, 2012 ²⁶26 Leite PMO, Tafuri L, Costa MZO, Lima MIM, Simões RT. Evaluation of the p16 and Ki-67 Biomarkers as Predictors of the Recurrence of Premalignant Cervical Cancer Lesions after LEEP Conization. Rev Bras Ginecol Obstet. 2017;39(6):288-93. DOI:10.1055/s-0037-1598643 https://doi.org/10.1055/s-0037-1598643...	326	CIN 2-3/tumor HIV+ and HIV -	P16 may be useful for CIN2-3 and tumor in well-defined situations
AMARO-FILHO et al, 2013 ⁹9 Amaro-Filho SM, Golub JE, Nuovo GJ, Cunha CB, Levi JE, Villa LL, et al. A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort. PLoS One. 2013;8(3):e57810. DOI:10.1371/journal.pone.0057810 https://doi.org/10.1371/journal.pone.005...	130	TMA with cervicitis/normal cervix, CIN 2-3 and tumor	p16 was more expressed in advanced FIGO stages

Mavera Edições Técnicas e Científicas Ltda Rua Professor Filadelfo Azevedo, 220, Cep: 04508-010, tel: (11) 3051 3043 - São Paulo - SP - Brazil
E-mail: medicalexpress@me.net.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] E-mail: afnnicol@gmail.com